My bull thesis has played out as the EV turnaround story delivered 100%+ gains, but the market is now mispricing Blue Bird Corporation by focusing on the wrong catalyst. While investors remain fixated ...
Bluebird Bio (BLUE) came out with a quarterly loss of $2.66 per share versus the Zacks Consensus Estimate of a loss of $3.60. This compares to loss of $7.20 per share a year ago. These figures are ...
SOMERVILLE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback